Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Dexanabinol: PARS will begin a double-blind Israeli Phase IIa trial in up to 200 patients, age ?60 years old, undergoing CS-CPB. Patients will be given 150 mg d

Pharmos Corp. (PARS), Iselin, N.J.
Product: Dexanabinol (HU-211)
Business: Neurological
Therapeutic category:

Read the full 126 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers